prilocaine
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Fortacin | — | 2013-11-15 | europa.eu ↗ |
| Approved | US (FDA) | CITANEST PLAIN | — | 1965-11-18 | fda.gov ↗ |
Trials 56 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05060913 | Nov 2021 → Mar 2022 | — | Dow University of Health Sciences | Completed | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT05062356 | Nov 2021 → Aug 2024 | chronic pain syndrome | St. Mary's Research Center, Canada | Completed | No outcome recorded |
| Phase 1 | NCT05912335 | Jun 2021 → Feb 2022 | tooth disorder | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 1 | NCT01324843 | Jun 2009 → May 2010 | — | National Institute on Aging (NIA) | Completed | No outcome recorded |
| Phase 1 | NCT01425840 | Mar → Nov 2008 | — | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 1 | NCT01054547 | Sep → Dec 2006 | — | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT05078463 | Sep 2021 → Aug 2022 | thalassemia | Universiti Kebangsaan Malaysia Medical Centre | Completed | No outcome recorded |
| Phase 2 | NCT03578783 | Dec 2018 → May 2021 | premature ejaculation | Plethora Solutions Ltd | Completed | No outcome recorded |
| Phase 2 | NCT03433976 | May 2018 → May 2020 | — | University Hospital, Montpellier | Unknown | No outcome recorded |
| Phase 2 | NCT03036384 | Mar → Nov 2016 | — | Centre Hospitalier Universitaire Saint Pierre | Completed | No outcome recorded |
| Phase 2 | NCT03607916 | Feb → Aug 2014 | — | Centre Hospitalier Universitaire Saint Pierre | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT06769204 | Feb → Aug 2025 overdue | female infertility | Cairo University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT03508804 | Dec 2020 → Dec 2022 | — | Stanford University | Withdrawn | No outcome recorded |
| Phase 3 | NCT02130830 | May 2014 → May 2016 | hemorrhoid | Pontificia Universidad Catolica de Chile | Completed | No outcome recorded |
| Phase 3 | NCT00959595 | Nov 2008 → Jan 2010 | diabetes mellitus | Lund University Hospital | Completed | No outcome recorded |
| Phase 423 trials | ||||||
| Phase 4 | NCT06767085 | Feb → Jul 2025 overdue | — | Cairo University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07329582 | May 2024 → Dec 2025 overdue | — | National University Hospital, Singapore | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06133881 | Dec 2023 → Feb 2024 | — | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT05970354 | Sep 2023 → Dec 2024 overdue | — | CAMC Health System | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT05834647 | Aug → Nov 2023 | local anesthetic poisoning | Universitas Sebelas Maret | Unknown | No outcome recorded |
| Phase 4 | NCT05984264 | Jan → Sep 2023 | — | Assiut University | Unknown | No outcome recorded |
| Phase 4 | NCT05649020 | Nov 2022 → Dec 2023 | — | Hospital General Universitario Gregorio Marañon | Unknown | No outcome recorded |
| Phase 4 | NCT05610007 | Jan → Aug 2022 | — | Indonesia University | Unknown | No outcome recorded |
| Phase 4 | NCT04394533 | Aug 2021 → Aug 2025 | cervical incompetence | Guy's and St Thomas' NHS Foundation Trust | Completed | No outcome recorded |
| Phase 4 | NCT04355598 | Apr → Aug 2020 | — | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT04003012 | Jul 2019 → Jul 2021 | lymphoid hemopathy | CAMC Health System | Completed | No outcome recorded |
| Phase 4 | NCT03071601 | Dec 2017 → Dec 2021 | — | Centre Hospitalier le Mans | Completed | No outcome recorded |
| Phase 4 | NCT02883179 | Oct 2016 → May 2017 | — | Assiut University | Completed | No outcome recorded |
| Phase 4 | NCT03072394 | Jan 2015 → Nov 2020 | coronary artery disorder | Hippocration General Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02384915 | Jan → May 2015 | osteoarthritis, knee | ASST Gaetano Pini-CTO | Completed | No outcome recorded |
| Phase 4 | NCT02372786 | Nov 2014 → Sep 2015 | acne keloid | Erasmus Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02246179 | Sep → Oct 2014 | — | Netherlands Institute for Pigment Disorders | Completed | No outcome recorded |
| Phase 4 | NCT01880775 | Apr 2012 → Jul 2013 | anal fistula, hemorrhoid | Diskapi Teaching and Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01412632 | Nov 2011 → Jul 2013 | leiomyoma, uterine polyp | University of Aarhus | Completed | No outcome recorded |
| Phase 4 | NCT01591616 | Apr 2010 → Apr 2012 | periodontal disorder | Dentsply International | Completed | No outcome recorded |
| Phase 4 | NCT02025361 | Feb 2009 → Dec 2012 | prostate adenocarcinoma | Bagcilar Training and Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01921231 | May 2007 | hernia, double inguinal | Dr. Pere Roura-Poch | Completed | No outcome recorded |
| Phase 4 | NCT00408941 | Dec 2006 | — | Technical University of Munich | Unknown | No outcome recorded |
| Phase not applicable18 trials | ||||||
| — | NCT07683182 | Nov 2025 → Jun 2026 overdue | — | Marmara University | Active not recruiting | No outcome recorded |
| — | NCT06891794 | Aug 2025 → Apr 2026 overdue | uterine inflammatory disease | Oregon Health and Science University | Recruiting | No outcome recorded |
| — | NCT07034456 | Jul 2025 → Jan 2026 overdue | — | Patricia Beltra Lopez | Not yet recruiting | No outcome recorded |
| — | NCT06600048 | Sep 2024 → Mar 2025 | — | Tanta University | Completed | No outcome recorded |
| — | NCT07664618 | Apr 2024 → May 2025 | — | Helwan University | Completed | No outcome recorded |
| — | NCT05877690 | Oct 2023 → Oct 2024 | — | Assiut University | Unknown | No outcome recorded |
| — | NCT05926895 | Jun 2023 → Aug 2024 | shoulder impingement syndrome | Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey | Completed | No outcome recorded |
| — | NCT06274905 | Feb → Jul 2023 | head and neck cancer, skin neoplasm | University Hospital Waterford | Completed | No outcome recorded |
| — | NCT07156968 | Jan 2022 → Feb 2023 | — | Ain Shams University | Completed | No outcome recorded |
| — | NCT05195177 | Nov 2021 → Dec 2023 | — | Aalborg University | Unknown | No outcome recorded |
| — | NCT04858360 | Nov 2021 → Aug 2022 | — | Aalborg University | Completed | No outcome recorded |
| — | NCT06507995 | Aug 2021 → Dec 2023 | chronic pain syndrome | Ankara University | Completed | No outcome recorded |
| — | NCT04076865 | Oct 2019 → Oct 2020 | — | Aalborg University | Completed | No outcome recorded |
| — | NCT01847157 | Jan 2013 → Jun 2015 | stroke disorder | National Taiwan University Hospital | Completed | No outcome recorded |
| — | NCT01628874 | Sep 2012 → Aug 2016 | — | University of Colorado, Denver | Terminated | No outcome recorded |
| — | NCT01402869 | Aug 2011 → Jul 2012 | methemoglobinemia | Loma Linda University | Completed | No outcome recorded |
| — | NCT01860235 | Jun 2010 → Mar 2012 | — | Franciscan University Center | Completed | No outcome recorded |
| — | NCT00309673 | — | tuberculosis | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 64 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT06680167 Comparator | Oct 2024 → Nov 2025 | — | Sohag University | Completed | No outcome recorded |
| Phase 0 | NCT02427724 Comparator | Apr 2015 → May 2024 | lentigo | Northwestern University | Completed | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT03313336 Comparator | Oct → Nov 2017 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT03441841 Comparator | Feb → Mar 2016 | — | Galeno Desenvolvimento de Pesquisas Clínicas | Completed | No outcome recorded |
| Phase 1 | NCT03325803 Background | Sep 2015 → Sep 2016 | actinic keratosis | Dong-A University | Completed | No outcome recorded |
| Phase 1 | NCT01073371 Comparator | Jul 2008 → Aug 2009 | — | University of Campinas, Brazil | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05694858 Comparator | Feb 2025 → Dec 2026 expected | cataract, glaucoma | Universiti Kebangsaan Malaysia Medical Centre | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06382220 Comparator | Apr → Jul 2024 | — | Fayoum University Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT05289804 Comparator | Sep 2022 → Dec 2025 | cognitive disorder, cognitive impairment with or without cerebellar ataxia | University of Dublin, Trinity College | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02658773 Comparator | Jan → May 2016 | — | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT00916942 Background | Jun 2009 | postherpetic neuralgia | NeurogesX | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT04523961 Comparator | Jan 2021 → Feb 2025 | local anesthetic poisoning | Mayo Clinic | Completed | No outcome recorded |
| Phase 2/3 | NCT00932542 Comparator | Apr 2010 → Feb 2011 | hemorrhoid | Federal University of São Paulo | Unknown | No outcome recorded |
| Phase 2/3 | NCT00556478 Comparator | Oct 2007 → Oct 2009 | premature ejaculation | Plethora Solutions Ltd | Completed | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT06703580 Comparator | Nov 2024 → Dec 2025 | — | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT06165679 Comparator | Dec 2023 → Jun 2025 | — | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT05726968 Comparator | Nov 2022 → Jun 2023 | — | Cairo University | Completed | No outcome recorded |
| Phase 3 | NCT02990364 Comparator | Dec 2015 → Dec 2016 | — | American University of Beirut Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT03366246 Comparator | Jun → Jul 2014 | — | Galeno Desenvolvimento de Pesquisas Clínicas | Completed | No outcome recorded |
| Phase 3 | NCT00444626 Background | May 2007 → Feb 2008 | — | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 419 trials | ||||||
| Phase 4 | NCT07564180 Comparator | May 2026 → May 2027 expected | — | Amr mohamed | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07546370 Comparator | Apr 2026 → Apr 2027 expected | — | Monakshi Sawhney | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07262398 Comparator | Aug → Dec 2024 | — | Theodor Bilharz Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT05609565 Comparator | Nov 2022 → Sep 2024 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT06540599 Comparator | Sep → Oct 2022 | — | Gaziosmanpasa Research and Education Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04784104 Background | Mar → Aug 2021 | — | Bozyaka Training and Research Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04756050 Background | Feb → Aug 2021 | brachial plexus neuropathy, diaphragma sellae meningioma, peripheral nerve lesion, respiratory paralysis | Bozyaka Training and Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03501212 Comparator | Apr → Jun 2019 | coronary vasospasm | Phramongkutklao College of Medicine and Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03799484 Background | Jan → Jun 2019 | — | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 4 | NCT04236115 Comparator | Sep 2017 → Apr 2018 | — | Taibah University | Completed | No outcome recorded |
| Phase 4 | NCT03264586 Comparator | Aug 2017 → Mar 2018 | — | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT03731988 Background | Feb → Oct 2017 | actinic keratosis | Dong-A University | Completed | No outcome recorded |
| Phase 4 | NCT02820688 Comparator | Jun → Oct 2016 | — | Bozyaka Training and Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03038958 Comparator | Apr → Jul 2016 | — | Centre Hospitalier Universitaire Saint Pierre | Completed | No outcome recorded |
| Phase 4 | NCT02548533 Comparator | Jun 2015 → Jan 2016 | — | Netherlands Institute for Pigment Disorders | Terminated | No outcome recorded |
| Phase 4 | NCT02549105 Comparator | Oct 2014 → Dec 2015 | — | Ain Shams Maternity Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01606046 Comparator | Jul 2011 | — | The Catholic University of Korea | Completed | No outcome recorded |
| Phase 4 | NCT01303614 Comparator | Apr 2011 → Apr 2012 | — | Consorci Sanitari de Terrassa | Unknown | No outcome recorded |
| Phase 4 | NCT01309360 Comparator | Sep 2009 → Apr 2010 | — | Helios Research Center | Completed | No outcome recorded |
| Phase not applicable25 trials | ||||||
| — | NCT07383571 Comparator | Oct 2025 → Apr 2026 | — | Cairo University | Completed | No outcome recorded |
| — | NCT05668286 Comparator | May → Nov 2024 | frozen shoulder | Kartal City Hospital | Unknown | No outcome recorded |
| — | NCT06290583 Comparator | Apr → Dec 2024 | — | South Valley University | Completed | No outcome recorded |
| — | NCT06416111 Comparator | Oct 2023 → Sep 2024 | chronic kidney disease | Ankara City Hospital Bilkent | Completed | No outcome recorded |
| — | NCT07174167 Comparator | Apr 2023 → Feb 2024 | osteoarthritis, knee | Haydarpasa Numune Training and Research Hospital | Completed | No outcome recorded |
| — | NCT05751148 Comparator | Mar → Sep 2023 | poisoning | Centre Hospitalier Universitaire Saint Pierre | Unknown | No outcome recorded |
| — | NCT06236178 Comparator | Jan → Oct 2023 | epicondylitis | Istanbul Training and Research Hospital | Completed | No outcome recorded |
| — | NCT05648708 Comparator | Nov 2022 → Aug 2023 | musculoskeletal system disorder | Bakirkoy Dr. Dr. Sadi Konuk Research and Training Hospital | Completed | No outcome recorded |
| — | NCT05688202 Comparator | Oct 2022 → Sep 2023 | skin atrophy | Ho Chi Minh City Hospital of Dermato-Venereology | Completed | No outcome recorded |
| — | NCT05891132 Comparator | Sep 2022 → Jul 2024 | — | Cairo University | Completed | No outcome recorded |
| — | NCT05042817 Comparator | Oct 2021 → Mar 2022 | — | University of Liege | Completed | No outcome recorded |
| — | NCT06885723 Comparator | Jul 2020 → Aug 2021 | sudden sensorineural hearing loss | Yuzuncu Yil University | Completed | No outcome recorded |
| — | NCT04050059 Comparator | Nov → Dec 2019 | — | Aga Khan University | Completed | No outcome recorded |
| — | NCT03220555 Comparator | Oct 2017 → Sep 2018 | — | Nantes University Hospital | Completed | No outcome recorded |
| — | NCT03219086 Comparator | Aug 2017 → May 2022 | — | University Hospital, Antwerp | Completed | No outcome recorded |
| — | NCT02726620 Background | Jan → Dec 2017 | hypotensive disorder | Vanderbilt University Medical Center | Completed | No outcome recorded |
| — | NCT03134391 Comparator | Aug → Oct 2016 | — | Indonesia University | Completed | No outcome recorded |
| — | NCT04378283 Comparator | May 2016 → Feb 2020 | — | University Medical Center Hamburg-Eppendorf | Completed | No outcome recorded |
| — | NCT02390310 Comparator | May 2015 → Jul 2016 | HIV infectious disease | EngenderHealth | Completed | No outcome recorded |
| — | NCT02016976 Comparator | Jan → Aug 2014 | — | Hillel Yaffe Medical Center | Unknown | No outcome recorded |
| — | NCT02336958 Comparator | Sep 2013 → Dec 2014 | carotid stenosis | Helios Research Center | Completed | No outcome recorded |
| — | NCT01845532 Comparator | Apr → Nov 2013 | leiomyoma | Yonsei University | Completed | No outcome recorded |
| — | NCT01425619 Comparator | Oct 2011 → Apr 2014 | allergic disease, anxiety disorder | Meir Medical Center | Completed | No outcome recorded |
| — | NCT01643616 Comparator | Nov 2010 → Jun 2012 | — | Helios Research Center | Completed | No outcome recorded |
| — | NCT06899438 Comparator | Aug 2009 → Jan 2010 | myofascial pain syndrome | Bursa City Hospital | Completed | No outcome recorded |
Evidence & citations 26 cited values
Every value below carries the sentence it was read from. 122 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | prilocaine | “EMLA Cream (Eutectic Mixture of Local Anesthetics) is an FDA-approved topical anesthetic comprised of 2.5% each of lidocaine/prilocaine. EMLA Cream was applied in approximately...” NCT00444626 ↗116“transrectal ultrasound guided 10 ml prilocaine and serum physiologic blend (5ml %2 prilocaine and 5 ml serum physiologic) injected separetly 5ml right and 5ml left junction...” NCT02025361 ↗ “The EMLA group received EMLA cream which consisted of 2.5% lidocaine and 2.5 % prilocaine in 2 ml of water/oil emulsion and then they received tegaderm as the dressing for...” NCT03134391 ↗ “At the start of session 2, one area of the middle forearms of the participant will be located (4x4cm). On the area, local anesthetic cream (2.5% lidocain/2.5 prilocaine) will...” NCT05195177 ↗ “EMLA®, a topical anesthetic cream containing lidocaine and prilocaine, will be applied under occlusion prior to tape application during 30 minutes with the aim of anesthetize...” NCT07034456 ↗ “liposome-encapsulated 2% ropivacaine, liposome-encapsulated 1% ropivacaine, a eutectic mixture of 2.5% lidocaine and 2.5% prilocaine (EMLA), and liposomal placebo gel,...” PMID 21106282 ↗ Nov 2010 “100 mg of the following formulations: Liposome-encapsulated 2,5% and 5% lidocaine gel, liposome placebo gel and 2.5% lidocaine and 2.5% prilocaine cream were applied once...” NCT01425840 ↗ “The purpose of this study is to compare the effects of vapocoolant spray and topical lidocaine 2.5% + prilocaine 2.5% cream (EMLA) on reducing pain during needle electromyography.” NCT01606046 ↗ “a local anaesthetic cream consisting of equal parts of lidocaine and prilocaine (1g contains 25 mg of lidocaine and 25 mg of prilocaine, AstraZeneca A/S, Albertslund, Denmark)” NCT04076865 ↗ “standard EMLA patch which is a eutectic emulsion mixture of lidocaine and prilocaine at 1:1 ratio (i.e. each gram of EMLA cream contains lidocaine and prilocaine, 25 mg each).” NCT05694858 ↗ “EMLA cream 5% 25g lidocaine, 25g prilocaine; Astra Zeneca. Topically applied followed by Tegaderm dressing to cover. Length of duration monitored and recorded as part of study” NCT06274905 ↗ “EMLA (eutectic mixture of local anesthetic) cream is the combination of lidocaine and prilocaine which have been effectively used in few studies to reduce needle prick pain.” NCT04050059 ↗ “EMLA® Test Patch containing the active ingredients lidocaine base 25 mg/g and prilocaine base 25 mg/g in an oil-in-water emulsion saturating the absorbent cellulose disc.” NCT03313336 ↗ “Effect of Local Anesthetic EMLA (Lidocaine 2.5% and Prilocaine 2.5%) Cream and Reduction in Dose, Pain and Intravenous Analgesic During Permanent Pacemaker Implantation” NCT02016976 ↗ “the prilocaine group underwent spinal anaesthesia with 60 mg intrathecal prilocaine; and the bupivacaine group received 12.5 mg intrathecal heavy bupivacaine.” PMID 33428221 ↗ Jan 2021 “PSD502 is a topical (applied to skin) anesthetic spray containing a mixture of two drugs called lidocaine and prilocaine that will be applied to the penis.” NCT03578783 ↗ “This research study uses Eutectic Mixture of Local Anesthetics (EMLA) Cream (lidocaine 2.5% and prilocaine 2.5%) as the topical anaesthetic agent.” NCT05078463 ↗ “In the Active Comparator arm, lidocaine 2.5% and prilocaine 2.5% cream placed over area where lumbar puncture will occur for at least 30 minutes.” NCT01628874 ↗ “EMLA cream is a eutectic mixture of 2.5% lidocaine and 2.5% prilocaine, used as a topical anaesthetic to diminish pain from cutaneous procedures.” NCT02990364 ↗ “hydrogels containing LAs - lidocaine and prilocaine (both at 2.5%) encapsulated in CLN (XAN-CLN) or not (XAN-CLN ), EMLA and placebo hydrogel” NCT05912335 ↗ “OBJECTIVE: To compare the anesthetic performances of 3% prilocaine and 4% articaine when used for the extraction of the maxillary teeth.” PMID 32934619 ↗ May 2020 “40 mg (low dose) intrathecal hyperbaric prilocaine 2% (Takipril, Sunny Medical group, Egypt under liscense from Sintetica, Switzerland)” NCT06382220 ↗ “EMLA cream with occluding dressing on the shoulder before surgery(5% of eutectic mixture with 2.5% lidocaine and 2.5% prilocaine)” NCT01845532 ↗ “EMLA anesthetic ointment (AO-Astra Zeneca) is an emulsion of lidocaine 2.5% and prilocaine 2.5% in a ratio of 1:1 by weight” NCT03501212 ↗ “Eutectic mixture of lidocaine 25 mg/g and prilocaine 25 mg/g cream (EMLA cream) will be applied at this test region at t1.” NCT02246179 ↗ “50 g of a local anesthetic agent containing 2.5% Lidocaine and 2.5% Prilocaine (EMLA®, AstraZeneca - Södertälje, Sweden)” NCT00959595 ↗ “Then one area will be pre-treated with cutaneous 2.5% lidocaine/2.5% prilocaine cream (EMLA cream) for 1 hour.” NCT04858360 ↗ “2 puffs of lidocaine-prilocaine spray into the cervix and cervical canal 5 minutes before the procedure” NCT06769204 ↗ “Group I received thoracic interlaminar epidural injections of 6 mL of 2% preservative-free prilocaine.” NCT06507995 ↗ “one cream will be an anesthetic (lidocaine and prilocaine) and the other will be a placebo lotion.” NCT01324843 ↗ “hyperbaric Prilocaine 2% in a reduced dose (30mg) in combination with Fentanyl (25µg)” NCT05726968 ↗ “a eutectic mixture containing 25 mg/g of lidocaine and 25 mg/g of prilocaine (EMLA®)” NCT01860235 ↗ “EMLA is a mixture of lidocaine (2.5%) and prilocaine (2.5%) in a cream base.” NCT04378283 ↗ “EMLA cream (lidocaine 2.5% and prilocaine 2.5% in a ratio of 1:1 by weight)” NCT03072394 ↗ “Eutectic Mixture of Local Anesthetics (Lidocaine 2.5% and Prilocaine 2.5%)” NCT05970354 ↗ “Patients using paracervical block with prilocaine for analgesia” NCT06540599 ↗ “topically applied lidocaine-prilocaine (EMLA) cream” NCT02549105 ↗ “Emla 5% cream (Lignocaine 2.5% / Prilocaine 2.5%)” NCT01847157 ↗ “EMLA cream (lidocaine 2.5% and prilocaine 2.5%)” NCT04003012 ↗ “lidocaine 25 mg/g + prilocaine 25 mg/g cream” NCT02548533 ↗ “2.5% prilocaine-2.5% lidocaine cream” NCT06891794 ↗ “2.5% Lidocaine and 2.5% Prilocaine” NCT05060913 ↗ “spinal anesthesia with prilocaine” NCT07156968 ↗ “EMLA cream (lidocaine+prilocaine)” NCT06885723 ↗ |
| Known as | ASTRA 1512 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1194 ↗ |
| Known as | ASTRA-1515 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1194 ↗ |
| Known as | citanest | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01412632 ↗ |
| Known as | Citanest hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL1194 ↗ |
| Known as | Citanest plain | ChEMBL registry synonym — accepted as the source's own label CHEMBL1194 ↗ |
| Known as | Citanest plain dental | ChEMBL registry synonym — accepted as the source's own label CHEMBL1194 ↗ |
| Known as | L-67 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1194 ↗ |
| Known as | NSC-40027 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1194 ↗ |
| Known as | NSC-758432 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1194 ↗ |
| Known as | Priloc | “Injection of 1 CC Betamethasone Dipropionate + Betamethasone Sodium Phosphate (Diprospan) and 4 cc 2% Prilocaine (Priloc)mixture into the subacromial space” NCT05926895 ↗ |
| Known as | Priloc %2 | “Autologous Blood Injection group were administered 1ml of autologous venous blood mixed with 2ml of 2% prilocaine HCl(Priloc %2,Vem,Turkey) subcutaneously.” NCT06236178 ↗ |
| Known as | Priloc HCl %2 | “20 ml of bupivacaine(Buvicaine HCl %0.5) and prilocaine(Priloc HCl %2) 1:1 mixture” NCT04756050 ↗ |
| Known as | Prilocaina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1194 ↗ |
| Known as | Prilocaine component of emla | ChEMBL registry synonym — accepted as the source's own label CHEMBL1194 ↗ |
| Known as | Prilocaine component of fortacin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1194 ↗ |
| Known as | Prilocaine component of oraqix | ChEMBL registry synonym — accepted as the source's own label CHEMBL1194 ↗ |
| Known as | Prilocaine HCl | “Those in the AB group were administered 1 ml of autologous venous blood mixed with 2 ml of 2% prilocaine HCl.” PMID 38963583 ↗ Jul 20241“EPINEPHrine 1:200,000 / Prilocaine HCl 4 % 1.8 ML Cartridge” NCT05062356 ↗ |
| Known as | prilocaine hydrochloride | “prilocaine 2% (Takipril, prilocaine hydrochloride 20 mg/mL, hyperbar, Sintetica)” NCT05726968 ↗2“prilocaine 2% (Takipril, prilocaine hydrochloride 20 mg/mL, hyperbar, Sintetica)” NCT06133881 ↗ |
| Known as | Propitocaine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1194 ↗ |
| Known as | Propitocaine hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL1194 ↗ |
| Known as | Takipril | “40 mg (low dose) intrathecal hyperbaric prilocaine 2% (Takipril, Sunny Medical group, Egypt under liscense from Sintetica, Switzerland)” NCT06382220 ↗2“prilocaine 2% (Takipril, prilocaine hydrochloride 20 mg/mL, hyperbar, Sintetica)” NCT06133881 ↗ “prilocaine 2% (Takipril, prilocaine hydrochloride 20 mg/mL, hyperbar, Sintetica)” NCT05726968 ↗ |
| Known as | Xylonest | ChEMBL registry synonym — accepted as the source's own label CHEMBL1194 ↗ |
| Action | Inhibit | “This lidocaine/prilocaine preparation blocks sodium channels in peripheral nerves in the skin” NCT05289804 ↗ |
| Modality | Small molecule | — CHEMBL1194 ↗ |
| Route | Topical | “Painful areas of up to a maximum of 1000 cm2 will be pre-treated with lidocaine (2.5%)/prilocaine (2.5%) cream for 60 minutes” NCT00916942 ↗ |